NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (US07585860-20090908-C00162.png) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (US07585860-20090908-C00162.png)
EP (6) EP1776962A1 (US07585860-20090908-C00162.png)
JP (4) JP2002540074A (US07585860-20090908-C00162.png)
KR (3) KR20020000785A (US07585860-20090908-C00162.png)
CN (3) CN1192798C (US07585860-20090908-C00162.png)
AR (3) AR022964A1 (US07585860-20090908-C00162.png)
AT (3) ATE459373T1 (US07585860-20090908-C00162.png)
AU (3) AU750913B2 (US07585860-20090908-C00162.png)
BE (1) BE1025464I2 (US07585860-20090908-C00162.png)
BR (4) BR0009163A (US07585860-20090908-C00162.png)
CA (3) CA2366314C (US07585860-20090908-C00162.png)
CY (3) CY1107561T1 (US07585860-20090908-C00162.png)
CZ (3) CZ303653B6 (US07585860-20090908-C00162.png)
DE (4) DE60038166T2 (US07585860-20090908-C00162.png)
DK (2) DK1163000T3 (US07585860-20090908-C00162.png)
ES (3) ES2300255T3 (US07585860-20090908-C00162.png)
FR (1) FR10C0008I2 (US07585860-20090908-C00162.png)
HK (3) HK1043728B (US07585860-20090908-C00162.png)
HU (4) HUP0200664A2 (US07585860-20090908-C00162.png)
IL (5) IL145045A0 (US07585860-20090908-C00162.png)
LU (1) LU91652I2 (US07585860-20090908-C00162.png)
MX (1) MXPA01009452A (US07585860-20090908-C00162.png)
MY (2) MY125202A (US07585860-20090908-C00162.png)
NL (1) NL300415I1 (US07585860-20090908-C00162.png)
NO (4) NO20014322L (US07585860-20090908-C00162.png)
NZ (3) NZ513841A (US07585860-20090908-C00162.png)
PL (3) PL203917B1 (US07585860-20090908-C00162.png)
PT (2) PT1163000E (US07585860-20090908-C00162.png)
SI (2) SI1162999T1 (US07585860-20090908-C00162.png)
TR (3) TR200102739T2 (US07585860-20090908-C00162.png)
TW (3) TWI286938B (US07585860-20090908-C00162.png)
WO (3) WO2000056358A2 (US07585860-20090908-C00162.png)

Families Citing this family (271)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) * 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunitƤt
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
CZ303653B6 (cs) 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. ImunogennĆ­ prostredek
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
EA006947B1 (ru) 2001-01-23 2006-06-30 ŠŠ²ŠµŠ½Ń‚Šøс ŠŸŠ°ŃŃ‚ŠµŃ€ ŠŸŠ¾Š»ŠøŠ²Š°Š»ŠµŠ½Ń‚Š½Š°Ń Š¼ŠµŠ½ŠøŠ½Š³Š¾ŠŗŠ¾ŠŗŠŗŠ¾Š²Š°Ń ŠæŠ¾Š»ŠøсŠ°Ń…Š°Ń€ŠøŠ“Š½Š¾-Š±ŠµŠ»ŠŗŠ¾Š²Š°Ń ŠŗŠ¾Š½ŃŠŃŽŠ³ŠøрŠ¾Š²Š°Š½Š½Š°Ń Š²Š°ŠŗцŠøŠ½Š°
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa FormulaƧƵes vacinais de influenza para distribuiĆ§Ć£o intradĆ©rmica
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2004032958A1 (en) 2002-10-11 2004-04-22 Chiron Srl Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
JP5116971B2 (ja) * 2002-10-15 2013-01-09 ć‚¤ćƒ³ć‚æćƒ¼ć‚»ćƒ« ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼¢ē¾¤é€£éŽ–ēƒčŒć®ęŽ„ē€å› å­ć‚’ć‚³ćƒ¼ćƒ‰ć™ć‚‹ę øé…ø态ļ½‚ē¾¤é€£éŽ–ēƒčŒć®ęŽ„ē€å› å­ć€ćŠć‚ˆć³ćć®ä½æē”Ø
ES2649048T3 (es) 2002-11-01 2018-01-09 Glaxosmithkline Biologicals S.A. Procedimiento de secado
CA2501077C (en) 2002-11-12 2016-06-21 Gerald B. Pier Polysaccharide vaccine for staphylococcal infections
EP2279746B1 (en) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
JP2006520746A (ja) 2002-12-27 2006-09-14 ć‚«ć‚¤ćƒ­ćƒ³ ć‚³ćƒ¼ćƒćƒ¬ć‚¤ć‚·ćƒ§ćƒ³ ćƒŖćƒ³č„‚č³Ŗć‚’å«ć‚€å…ē–«åŽŸę€§ēµ„ęˆē‰©
FR2850106B1 (fr) * 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
WO2004067030A2 (en) * 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
AU2004220590B2 (en) * 2003-03-07 2010-02-18 Inhibitex, Inc. Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US8084235B2 (en) * 2003-03-13 2011-12-27 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
CA2520124A1 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of benzazole compounds for immunopotentiation
PL1631264T5 (pl) 2003-06-02 2018-09-28 Glaxosmithkline Biologicals Sa Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
ATE506963T1 (de) * 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integraĆ§Ć£o de vacinaĆ§Ć£o com conjugado meningocĆ³cico
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
CN101203529A (zh) 2005-02-18 2008-06-18 čÆŗ华ē–«č‹—å’ŒčÆŠę–­å…¬åø ę„č‡Ŗ脑膜ē‚Ž/脓ęƒē—‡ē›øå…³ę€§å¤§č‚ ę†čŒēš„蛋ē™½č“Ø和ę øé…ø
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CN102716480B (zh) 2005-04-08 2023-03-21 ęƒ ę°ęœ‰é™č“£ä»»å…¬åø 多价č‚ŗē‚ŽēƒčŒå¤šē³–-蛋ē™½č“Øē¼€åˆē‰©ē»„合ē‰©
WO2006113528A2 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
KR101408113B1 (ko) 2005-06-27 2014-06-16 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė°±ģ‹  ģ œģ”° ė°©ė²•
BRPI0615420A2 (pt) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic vacinaĆ§Ć£o mĆŗltipla que inclui meningococo do sorogrupo c
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
CA2808919C (en) * 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI0707154B8 (pt) * 2006-01-17 2022-12-20 Forsgren Arne composiĆ§Ć£o de vacina
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
KR101411425B1 (ko) * 2006-03-17 2014-06-24 ė” ź±°ė²„ėؼķŠø ģ˜¤ėøŒ ė” ģœ ė‚˜ģ“ķ‹°ė“œ ģŠ¤ķ…Œģ“ģø  ģ˜¤ėøŒ ģ•„ė©”ė¦¬ģ¹“ ģ—ģ¦ˆ ė ˆķ”„ė¦¬ģ  ķ‹°ė“œ ė°”ģ“ ė” ģ„øķ¬ėŸ¬ķ…Œė¦¬ ģ˜¤ėøŒ ė” ė””ķŒŒķŠøėؼķŠø ģ˜¤ėøŒ ķ—¬ģŠ¤ ģ•¤ė“œ ķœ“ėؼ ģ„œė¹„ģ‹œģ¦ˆ ė³µķ•© ė‹¤ź°€ ė©“ģ—­ģ›ģ„± ģ½˜ģ„¬ź²Œģ“ķŠøģ˜ ģ œģ”° ė°©ė²•
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
JO3418B1 (ar) * 2006-03-30 2019-10-20 Glaxosmithkline Biologicals Sa Ų¹Ł…Ł„ŁŠŲ© Ų§Ł‚ŲŖŲ±Ų§Ł† Ų®Ų§ŲµŲ© ŲØ pnag ŁˆŲØŲ±ŁˆŲŖŁŠŁ† Ų­Ų§Ł…Ł„
EP2476434A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US20110206692A1 (en) * 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
JP2010500399A (ja) 2006-08-16 2010-01-07 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ å°æč·Æē—…åŽŸę€§å¤§č…ø菌ē”±ę„ć®å…ē–«åŽŸ
CL2007002909A1 (es) * 2006-10-10 2008-04-18 Wyeth Corp Metodo para reduccion o extraccion de impurezas de proteinas a partir de lisado celular de streptoccocus pneumoniae que comprende calentar dicho lisado, separar a los precipitantes a partir de dicho lisado produciendo un lisado que contiene polisacar
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2687228B1 (en) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR101621837B1 (ko) 2007-09-12 2016-05-17 ė…øķŒŒė„“ķ‹°ģŠ¤ ģ•„ź²Œ ļ¼§ļ½ļ½“57 ėŒģ—°ė³€ģ“ ķ•­ģ› ė° ļ½‡ļ½ļ½“57 ķ•­ģ²“
JP5701058B2 (ja) 2007-10-19 2015-04-15 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ é«„č†œē‚ŽčŒćƒÆć‚Æćƒćƒ³å‡¦ę–¹ē‰©
WO2009062132A2 (en) 2007-11-09 2009-05-14 California Institute Of Technology Immunomodulating compounds and related compositions and methods
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN104292312A (zh) 2007-12-21 2015-01-21 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø 链ēƒčŒęŗ¶č”€ē“ oēš„ēŖå˜å½¢å¼
WO2009094730A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
EP2631245A1 (en) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
RU2532911C2 (ru) 2008-07-21 2014-11-20 Š”Š·Šµ Š‘Ń€ŠøхэŠ¼ Š­Š½Š“ Š£ŠøŠ¼ŠµŠ½'Š— Š„Š¾ŃŠæŠøтŠ°Š», Š˜Š½Šŗ. Š”ŠæŠ¾ŃŠ¾Š±Ń‹ Šø ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø, Š¾Ń‚Š½Š¾ŃŃŃ‰ŠøŠµŃŃ Šŗ сŠøŠ½Ń‚ŠµŃ‚ŠøчŠµŃŠŗŠøŠ¼ Š±ŠµŃ‚Š°-1,6-Š³Š»ŃŽŠŗŠ¾Š·Š°Š¼ŠøŠ½Š¾Š»ŠøŠ³Š¾ŃŠ°Ń…Š°Ń€ŠøŠ“Š°Š¼
ES2586308T3 (es) 2008-10-27 2016-10-13 Glaxosmithkline Biologicals Sa Procedimiento de purificaciĆ³n de un hidrato de carbono de Streptococcus del grupo A
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
AU2010203223B9 (en) 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
CA2756533A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
PL2510947T3 (pl) 2009-04-14 2016-09-30 Kompozycje do immunizacji przeciwko Staphylococcus aureus
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
JP2012530785A (ja) 2009-06-22 2012-12-06 ćƒÆć‚¤ć‚¹ćƒ»ć‚Ø惫ć‚Øćƒ«ć‚·ćƒ¼ ēµ„ęˆē‰©ćŠć‚ˆć³é»„č‰²ćƒ–ćƒ‰ć‚¦ēƒčŒļ¼ˆļ¼³ļ½”ļ½ļ½ļ½ˆļ½™ļ½Œļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ļ½ļ½•ļ½’ļ½…ļ½•ļ½“ļ¼‰č”€ęø…åž‹ļ¼•ćŠć‚ˆć³ļ¼˜čŽ¢č†œå¤šē³–ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆå…ē–«åŽŸę€§ēµ„ęˆē‰©ć‚’čŖæč£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
KR20130127547A (ko) 2009-07-30 2013-11-22 ķ™”ģ“ģž ė°±ģ‹ ģŠ¤ ģ—˜ģ—˜ģ”Ø ķ•­ģ›ģ„± ķƒ€ģš° ķŽ©ķƒ€ģ“ė“œ ė° ģ“ģ˜ ģš©ė„
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
ES2670576T3 (es) * 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
CN102695523A (zh) 2009-09-10 2012-09-26 čÆŗåŽęœ‰é™å…¬åø 针åƹ呼åø道ē–¾ē—…ēš„ē»„合ē–«č‹—
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptĆ­deos de modificaĆ§Ć£o meningocĆ³cica fhbp"
JP5914344B2 (ja) 2009-10-30 2016-05-11 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼³ļ½”ļ½ļ½ļ½ˆļ½™ļ½Œļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ļ½ļ½•ļ½’ļ½…ļ½•ļ½“ļ¼•åž‹ćŠć‚ˆć³ļ¼˜åž‹ć®čŽ¢č†œē³–恮ē²¾č£½
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011084705A2 (en) 2009-12-17 2011-07-14 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
SG10201408505SA (en) 2009-12-22 2015-02-27 Celldex Therapeutics Inc Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
ES2910199T3 (es) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland ProteĆ­nas de uniĆ³n al factor H (fHbp) con propiedades alteradas y mĆ©todos de uso de las mismas
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US20110251156A1 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
JP2013530949A (ja) * 2010-05-20 2013-08-01 ć‚Ø惫 ćƒ©ć‚¦ćƒ³ćƒ‰ ć‚øćƒ„ćƒ¼ćƒ³ ęŠ—åŽŸē‰¹ē•°ēš„ļ¼“ļ½’ļ½…ļ½‡äø¦ć³ć«é–¢é€£ć™ć‚‹ēµ„ęˆē‰©ć€ę–¹ę³•åŠć³ć‚·ć‚¹ćƒ†ćƒ 
PL3170508T3 (pl) * 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
US20130203980A1 (en) 2011-05-06 2013-08-08 Petr Gennadievich Aparin Exopolysaccharide of shigella sonnei bacteria, method for producing same, vaccine and pharmaceutical composition containing same
BR112013032410A2 (pt) 2011-06-24 2017-01-17 Epitogenesis Inc composiƧƵes farmacĆŖuticas compreendendo uma combinaĆ§Ć£o de veĆ­culos, vitaminas, taninos e flavonoides de seleĆ§Ć£o como imunomoduladores especĆ­ficos de antĆ­geno
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
SG11201402375VA (en) 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
AU2013224026A1 (en) 2012-02-24 2014-08-21 Novartis Ag Pilus proteins and compositions
JP2015510872A (ja) 2012-03-07 2015-04-13 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼³ļ½”ļ½’ļ½…ļ½ļ½”ļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ļ½ļ½Žļ½…ļ½•ļ½ļ½ļ½Žļ½‰ļ½ļ½…ęŠ—åŽŸć®å¢—å¼·ć•ć‚ŒćŸč£½å‰¤
CN104159603A (zh) 2012-03-08 2014-11-19 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø åø¦ęœ‰tlr4ęæ€åŠØ剂ēš„č”åˆē–«č‹—
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
RU2727476C2 (ru) 2012-04-26 2020-07-21 ŠŠ¾Š²Š°Ń€Ń‚Šøс ŠŠ³ ŠŠ½Ń‚ŠøŠ³ŠµŠ½Ń‹ Šø Š°Š½Ń‚ŠøŠ³ŠµŠ½Š½Ń‹Šµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
JP2015518845A (ja) 2012-05-22 2015-07-06 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ é«„č†œē‚ŽčŒč”€ęø…ē¾¤ļ½˜ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆ
KR102057217B1 (ko) 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
RU2015106930A (ru) 2012-09-06 2016-10-20 ŠŠ¾Š²Š°Ń€Ń‚Šøс ŠŠ³ ŠšŠ¾Š¼Š±ŠøŠ½ŠøрŠ¾Š²Š°Š½Š½Ń‹Šµ Š²Š°ŠŗцŠøŠ½Ń‹ с Š¼ŠµŠ½ŠøŠ½Š³Š¾ŠŗŠ¾ŠŗŠŗŠ¾Š¼ сŠµŃ€Š¾Š³Ń€ŃƒŠæŠæы Š² Šø Šŗ/Š“/с
US9855324B2 (en) 2012-10-03 2018-01-02 Glaxosmithkline Biologicals Sa Immunogenic compositions
BR112015008040A2 (pt) 2012-10-12 2017-07-04 Glaxosmithkline Biologicals Sa composiĆ§Ć£o de vacina, vacina de combinaĆ§Ć£o, e, processos para preparar um componente ap e para a fabricaĆ§Ć£o de uma composiĆ§Ć£o de vacina
KR20150072444A (ko) * 2012-10-17 2015-06-29 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ķ•˜ė‚˜ ģ“ģƒģ˜ ģŠ¤ķŠøė ™ķ† ģ½”ģ»¤ģŠ¤ ė‰“ėŖØė‹ˆģ•  ģŗ”ģŠ ģ‚¬ģ¹“ė¼ģ“ė“œ ģ»Øģ„¬ź²Œģ“ķŠø ė° ķ•“ėŖØķ•„ė£ØģŠ¤ ģøķ”Œė£Øģ—”ģžė”œė¶€ķ„°ģ˜ ė‹Øė°±ģ§ˆ ļ¼„ ė°ļ¼ė˜ėŠ” ļ¼°ļ½‰ļ½Œļ¼”ė„¼ ķ¬ķ•Øķ•˜ėŠ” ė‹Øė°±ģ§ˆ ģ„±ė¶„ģ„ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
CN105188747A (zh) 2013-02-01 2015-12-23 č‘›å…°ē“ å²åƆę–Æå…‹čŽ±ē”Ÿē‰©å…¬åø 包含tollę ·å—ä½“ęæ€åŠØ剂ēš„免ē–«ē»„合ē‰©ēš„ēš®å†…递送
JP2016521284A (ja) 2013-05-10 2016-07-21 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒćƒ„ćƒ¼ćƒˆ ć‚Ŗ惖 惆ć‚Æ惎惭ć‚øćƒ¼ 大č…øć‚¬ćƒ³ć®ćƒ—ćƒ­ćƒć‚¤ć‚Ŗćƒ†ć‚£ć‚Æć‚¹ć«ć‚ˆć‚‹é˜²ę­¢ćŠć‚ˆć³å‡¦ē½®
CN112999344A (zh) 2013-05-15 2021-06-22 é˜æ尔ä¼Æč¾¾å¤§å­¦č‘£äŗ‹ä¼š E1e2 hcvē–«č‹—及ä½æē”Øę–¹ę³•
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
RU2710393C2 (ru) * 2014-01-21 2019-12-26 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š˜Š½Šŗ. Š”ŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя ŠøŠ¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Š¾Š³Š¾ ŠŗŠ¾Š½ŃŠŃŽŠ³Š°Ń‚Š° ŠŗŠ°ŠæсуŠ»ŃŒŠ½Ń‹Š¹ ŠæŠ¾Š»ŠøсŠ°Ń…Š°Ń€ŠøŠ“ Streptococcus pneumoniae-Š±ŠµŠ»Š¾Šŗ-Š½Š¾ŃŠøтŠµŠ»ŃŒ
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PL3096785T3 (pl) 2014-01-21 2021-03-08 Pfizer Inc. Kompozycje immunogenne zawierające skoniugowane antygeny sacharydĆ³w otoczkowych i ich zastosowania
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
BR112016019735A2 (pt) 2014-02-28 2017-10-17 Glaxosmithkline Biologicals Sa fhbp, polipeptĆ­deo, plasmĆ­deo ou outro Ć”cido nucleico, cĆ©lula hospedeira, vesĆ­culas de membrana, e, composiĆ§Ć£o imunogĆŖnica
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
WO2016014719A1 (en) 2014-07-23 2016-01-28 Children's Hospital & Research Center Oakland Factor h binding protein variants and methods of use thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
EP3244917B1 (en) 2015-01-15 2023-04-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
JP2018522885A (ja) 2015-07-07 2018-08-16 ć‚¢ćƒ•ć‚£ćƒŖć‚¹ćƒ»ć‚¢ć‚Æćƒć‚§ćƒ³ć‚²ć‚¼ćƒ«ć‚·ćƒ£ćƒ•ćƒˆļ¼”ļ½†ļ½†ļ½‰ļ½’ļ½‰ļ½“ ļ¼”ļ½‡ ļ¼©ļ½‡ļ¼„介åœØꀧē–¾ę‚£ć®å‡¦ē½®ćŠć‚ˆć³äŗˆé˜²ć®ćŸć‚ć®ćƒÆć‚Æćƒćƒ³
MY192183A (en) 2015-07-21 2022-08-05 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ č‚ŗē‚Žé€£éŽ–ēƒčŒćƒÆć‚Æćƒćƒ³ć«ćŠć„ć¦ē”Øć„ć‚‹ćŸć‚ć®å…ē–«åŽŸę€§ēµ„ęˆē‰©
MX2018006785A (es) 2015-12-04 2018-11-09 Dana Farber Cancer Inst Inc Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer.
ES2811523T3 (es) 2016-01-19 2021-03-12 Pfizer Vacunas contra el cƔncer
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
EP3474890A1 (en) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Fƶrderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2017306708B2 (en) 2016-08-05 2021-08-26 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
JP7104027B2 (ja) 2016-09-02 2022-07-20 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ę·‹čŒć«åÆ¾ć™ć‚‹ćƒÆć‚Æćƒćƒ³
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
EP3522915A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
CN110198735A (zh) 2017-01-20 2019-09-03 č¾‰ē‘žå…¬åø ē”ØäŗŽč‚ŗē‚ŽēƒčŒē–«č‹—äø­ēš„免ē–«åŽŸę€§ē»„合ē‰©
CN110234658B (zh) 2017-01-31 2024-03-12 č¾‰ē‘žå¤§čÆ厂 脑膜ē‚Žå„ˆē‘ŸčŒē»„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110520154B (zh) * 2017-03-15 2023-08-04 ę Ŗ式会ē¤¾Lg化学 多价č‚ŗē‚Žé“¾ēƒčŒē–«č‹—ē»„合ē‰©
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
CN110662557A (zh) 2017-03-31 2020-01-07 č‘›å…°ē“ å²å…‹ēŸ„čƆäŗ§ęƒå¼€å‘ęœ‰é™å…¬åø 免ē–«åŽŸę€§ē»„合ē‰©ć€ē”Øé€”å’Œę²»ē–—ę–¹ę³•
BR112019026192B1 (pt) 2017-06-10 2022-05-10 Inventprise, Llc Vacinas de conjugado multivalente com polissacarĆ­deos de conjugado bivalente ou multivalente que fornecem imunogenicidade e avidez melhoradas
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
EP3641808A1 (en) 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Methods of boosting immune responses
GEP20227420B (en) 2017-12-06 2022-10-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2019215216A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2020007939A (es) 2018-02-05 2020-09-03 Sanofi Pasteur Inc Composicion del conjugado proteina-polisacarido multivalente nuemococica.
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
EP3773689B1 (en) 2018-04-11 2022-11-09 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
BR112020021296A2 (pt) 2018-04-18 2021-01-26 Sk Bioscience Co., Ltd. polissacarĆ­deo capsular de streptococcus pneumoniae e conjugado imunogĆŖnico do mesmo
JP7446279B2 (ja) 2018-07-19 2024-03-08 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ä¹¾ē‡„多ē³–ć‚’čŖæč£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2022512345A (ja) 2018-12-12 2022-02-03 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ 免ē–«åŽŸę€§å¤šé‡ćƒ˜ćƒ†ćƒ­ęŠ—原多ē³–ļ¼ć‚æćƒ³ćƒ‘ć‚Æč³Ŗć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆćŠć‚ˆć³ćć®ä½æē”Ø
JP2022513458A (ja) 2018-12-12 2022-02-08 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ļ¼Æļ¼ēµåˆåž‹ć‚°ćƒŖć‚³ć‚·ćƒ«åŒ–ć®ćŸć‚ć®äæ®é£¾ć‚­ćƒ£ćƒŖć‚¢ć‚æćƒ³ćƒ‘ć‚Æč³Ŗ
JOP20210148A1 (ar) 2018-12-19 2023-01-30 Merck Sharp & Dohme ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ ŲŖŲ“ŲŖŁ…Ł„ Ų¹Ł„Ł‰ Ł…ŲŖŁ‚Ų§Ų±Ł†Ų§ŲŖ ŲØŁˆŁ„ŁŠ Ų³ŁƒŲ§Ų±ŁŠŲÆ-ŲØŲ±ŁˆŲŖŁŠŁ† Ł„Ł„Ł…ŁƒŁˆŲ±Ų§ŲŖ Ų§Ł„Ų¹Ł‚ŲÆŁŠŲ© Ų§Ł„Ų±Ų¦ŁˆŁŠŲ© ŁˆŲ·Ų±Ł‚ Ų§Ų³ŲŖŲ®ŲÆŲ§Ł…Ł‡Ų§
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
CA3139257A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
US20230248816A9 (en) 2019-08-05 2023-08-10 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
EP4010014A1 (en) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112022007203A2 (pt) 2019-10-16 2022-07-05 Enterome S A Compostos imunogĆŖnicos para tratamento de cĆ¢ncer adrenal
KR20220092572A (ko) 2019-11-01 2022-07-01 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ—ģŠ¤ģ¼€ė¦¬ķ‚¤ģ•„ ģ½œė¼ģ“ ģ”°ģ„±ė¬¼ ė° ź·ø ė°©ė²•
BR112022009100A2 (pt) 2019-11-15 2022-07-26 Enterome S A PeptĆ­deos antigĆŖnicos para prevenĆ§Ć£o e tratamento de malignidade de cĆ©lulas b
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
CA3171864A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
CN115605498A (zh) 2020-02-23 2023-01-13 č¾‰ē‘žå…¬åøļ¼ˆUsļ¼‰ å¤§č‚ ę†čŒē»„合ē‰©åŠå…¶ę–¹ę³•
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
KR20230097160A (ko) 2020-11-04 2023-06-30 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ķė “źµ¬ź·  ė°±ģ‹ ģ— ģ‚¬ģš©ķ•˜źø° ģœ„ķ•œ ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼
WO2022101745A2 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
IL305313A (en) 2021-02-19 2023-10-01 Sanofi Pasteur Recombinant meningococcal B vaccine
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
TW202306969A (zh) 2021-05-28 2023-02-16 ē¾Žå•†č¼ē‘žå¤§č—„å»  包含ēµåˆä¹‹čŽ¢č†œé†£ęŠ—原ēš„免ē–«åŽŸēµ„合ē‰©åŠå…¶ē”Ø途
BR112023023671A2 (pt) 2021-05-28 2024-02-06 Pfizer ComposiƧƵes imunogĆŖnicas compreendendo antĆ­genos de sacarĆ­deo capsular conjugados e usos dos mesmos
CA3237496A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230116601A (ko) 2022-01-28 2023-08-04 ģ“ė™ėƼ ėØøģ‹  ģ¢Œķ‘œź³„ģ™€ ģ˜ģƒ ģ¢Œķ‘œź³„ģ˜ ģ •ķ•© ė°©ė²• ė° ģž„ģ¹˜
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JP3237842B2 (ja) * 1988-12-16 2001-12-10 ć‚Ŗćƒ©ćƒ³ćƒ€å›½ ćƒ‹ćƒ„ćƒ¼ćƒ¢ćƒŖć‚·ćƒ³ćƒŸćƒ„ćƒ¼ć‚æćƒ³ćƒˆåŠć³ćć‚Œć‹ć‚‰č£½é€ ć•ć‚ŒćŸćƒ‹ćƒ„ćƒ¼ćƒ¢ć‚³ćƒƒć‚«ćƒ«ćƒÆć‚Æćƒćƒ³
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
DE69331437T2 (de) * 1992-09-16 2002-09-05 Univ Tennessee Res Corp Antigene des hybriden m-proteins und trƤger fĆ¼r gruppe a streptokokkenimpfstoff
HU219056B (hu) 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazĆ³ vakcinakĆ©szĆ­tmĆ©ny
EP1300156A3 (en) 1993-05-18 2003-05-07 The Ohio State University Research Foundation Otitis media vaccine
JP3828145B2 (ja) 1993-09-22 2006-10-04 ćƒ˜ćƒ³ćƒŖćƒ¼ ć‚Ø惠ļ¼Žć‚øćƒ£ć‚Æć‚½ćƒ³ ćƒ•ć‚”ć‚¦ćƒ³ćƒ‡ć‚¤ć‚·ćƒ§ćƒ³ ćƒ•ć‚©ćƒ¼ 悶 ć‚¢ćƒ‰ćƒćƒ³ć‚¹ćƒ”ćƒ³ćƒˆ ć‚Ŗ惖 惟ćƒŖć‚æćƒŖćƒ¼ ćƒ”ćƒ‡ć‚£ć‚¹ćƒ³ 免ē–«åŽŸę€§ę§‹ęˆē‰©ć®č£½é€ ć®ćŸć‚ć®ę–°č¦ć‚·ć‚¢ćƒ³åŒ–試薬悒ä½æć£ćŸåÆęŗ¶ę€§ē‚­ę°“化ē‰©ć®ę“»ę€§åŒ–ę–¹ę³•
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
KR19990007858A (ko) * 1995-04-17 1999-01-25 ģ”“ ė”ėø”ģœ .ė”œģš° ė°•ķ…Œė¦¬ģ•„ģ˜ ė¦¬ķ¬ķ”„ė”œķ…Œģøģœ¼ė”œ ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œģ— ėŒ€ķ•œ ė©“ģ—­ė°˜ģ‘ģ˜ ģœ ė„ė° ź°•ķ™”
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
BR9608612A (pt) 1995-06-07 1999-05-04 Smithkline Beecham Biolog Vacina compreendendo um conjugado de antĆ­geno de polissacarĆ­deo - proteĆ­na portadora e proteĆ­na portadora livre
JPH11507214A (ja) 1995-06-07 1999-06-29 惐悤ć‚Ŗć‚±ćƒ  ćƒ“ć‚”ć‚·ćƒ¼ćƒ³ć‚ŗ ć‚¤ćƒ³ć‚Æļ¼Ž ļ¼Øļ½“ļ½ļ¼—ļ¼ćƒ•ć‚”惟ćƒŖćƒ¼ć«å±žć™ć‚‹é€£éŽ–ēƒčŒć®ē†±ć‚·ćƒ§ćƒƒć‚Æ蛋ē™½č³Ŗćƒ”ćƒ³ćƒćƒ¼
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
ATE323721T1 (de) 1996-05-01 2006-05-15 Univ Rockefeller Cholin-bindendes protein, welches als gegen pneumokokken gerichtetes vakzin verwendet wird
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
AU739129B2 (en) 1997-06-03 2001-10-04 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
KR100619350B1 (ko) 1997-07-21 2006-09-05 ė°•ģŠ¤ķ„° ķ—¬ģ“°ģ¼€ģ–“ ģ—ģŠ¤.ģ—ģ“. ė³€ķ˜• ė©“ģ—­ģ„± ė‰“ė©€ė¦¬ģ‹  ė°±ģ‹ ģ”°ģ„±ė¬¼
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
EP1067962B1 (en) 1998-04-07 2010-03-24 MedImmune, LLC Derivatives of pneumococcal choline binding proteins for vaccines
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
CN1263510C (zh) 1998-08-19 2006-07-12 å·“å…‹ę–Æē‰¹å„åŗ·ęŠ¤ē†č‚”ä»½ęœ‰é™å…¬åø 多ē³–ļ¼č›‹ē™½č“Øē¼€åˆē‰©ęˆ–åÆ”ē³–ļ¼č›‹ē™½č“Øē¼€åˆē‰©ć€å…¶åˆ¶å¤‡ę–¹ę³•åŠå…¶åŗ”ē”Ø
JP4689044B2 (ja) * 1998-12-21 2011-05-25 ćƒ”ćƒ‡ć‚£ćƒŸćƒ„ćƒ¼ćƒ³ļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ ćƒÆć‚Æćƒćƒ³ē”Ø恮č‚ŗē‚Žé€£éŽ–ēƒčŒć‚æćƒ³ćƒ‘ć‚Æč³ŖćØ免ē–«åŽŸę–­ē‰‡
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CZ303653B6 (cs) * 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. ImunogennĆ­ prostredek
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
DE60032120T2 (de) 2007-09-20
CY1107561T1 (el) 2013-03-13
CZ20013378A3 (cs) 2002-03-13
SI1163000T1 (sl) 2008-06-30
HUP0200367A2 (en) 2002-05-29
AR022963A1 (es) 2002-09-04
BRPI0009163B1 (pt) 2019-04-09
CZ20013379A3 (cs) 2002-03-13
KR20020000785A (ko) 2002-01-05
CN1351503A (zh) 2002-05-29
US20100119544A1 (en) 2010-05-13
CN1391481A (zh) 2003-01-15
ES2339737T3 (es) 2010-05-25
IL145043A (en) 2007-06-17
NO330532B1 (no) 2011-05-09
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
NZ513841A (en) 2001-09-28
KR20020001785A (ko) 2002-01-09
TWI281403B (en) 2007-05-21
CZ303653B6 (cs) 2013-01-30
TR200102739T2 (tr) 2001-12-21
MXPA01009452A (es) 2002-08-06
AU750762B2 (en) 2002-07-25
EP1162999A2 (en) 2001-12-19
JP4846906B2 (ja) 2011-12-28
IL145044A0 (en) 2002-06-30
PL355180A1 (en) 2004-04-05
ES2300255T3 (es) 2008-06-16
EP1162998A2 (en) 2001-12-19
EP1776962A1 (en) 2007-04-25
HUS1500040I1 (hu) 2018-05-28
JP2002540074A (ja) 2002-11-26
IL145045A0 (en) 2002-06-30
EP1880735A3 (en) 2008-03-12
AU3430700A (en) 2000-10-09
AU750913B2 (en) 2002-08-01
BR0009163A (pt) 2001-12-26
CN1351501A (zh) 2002-05-29
WO2000056358A2 (en) 2000-09-28
NO20014322L (no) 2001-11-14
EP1163000B1 (en) 2008-02-27
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
ATE387214T1 (de) 2008-03-15
BR0009166A (pt) 2001-12-26
US20050031646A1 (en) 2005-02-10
NZ513842A (en) 2004-05-28
MY125387A (en) 2006-07-31
HK1043728A1 (en) 2002-09-27
WO2000056360A2 (en) 2000-09-28
CN1191852C (zh) 2005-03-09
JP2011057713A (ja) 2011-03-24
US20030147922A1 (en) 2003-08-07
AR022964A1 (es) 2002-09-04
IL145043A0 (en) 2002-06-30
HU229968B1 (hu) 2015-03-30
NL300415I1 (nl) 2009-12-01
NO2011014I2 (no) 2011-08-30
IL145044A (en) 2007-03-08
PL203917B1 (pl) 2009-11-30
BR0009154A (pt) 2001-12-26
TR200102735T2 (tr) 2002-04-22
AR022965A1 (es) 2002-09-04
MY125202A (en) 2006-07-31
NZ513840A (en) 2004-02-27
AU3291900A (en) 2000-10-09
CN1192798C (zh) 2005-03-16
NO20014325L (no) 2001-11-14
ATE459373T1 (de) 2010-03-15
DE60038166D1 (de) 2008-04-10
US20110217329A1 (en) 2011-09-08
KR100798212B1 (ko) 2008-01-24
EP1880735A2 (en) 2008-01-23
NO20014322D0 (no) 2001-09-05
EP1162998B1 (en) 2010-03-03
US20060093626A1 (en) 2006-05-04
CY2009014I1 (el) 2010-07-28
NO20014323D0 (no) 2001-09-05
TR200102736T2 (tr) 2002-04-22
HUP0200373A2 (en) 2002-06-29
HK1043728B (zh) 2007-06-22
EP2277535A3 (en) 2011-03-09
US8926985B2 (en) 2015-01-06
EP2277535A2 (en) 2011-01-26
PT1162999E (pt) 2007-02-28
WO2000056359A3 (en) 2001-02-01
NO330736B1 (no) 2011-06-27
PL204890B1 (pl) 2010-02-26
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
CA2365296A1 (en) 2000-09-28
PL355264A1 (en) 2004-04-05
TWI235064B (en) 2005-07-01
WO2000056360A3 (en) 2001-01-25
DK1162999T3 (da) 2007-03-26
CY1107390T1 (el) 2010-07-28
US9168313B2 (en) 2015-10-27
NO2011014I1 (no) 2011-09-19
JP2002539273A (ja) 2002-11-19
DE60032120D1 (de) 2007-01-11
NO20014325D0 (no) 2001-09-05
HK1043731B (zh) 2009-01-23
CA2366314C (en) 2012-01-10
DE60043930D1 (de) 2010-04-15
ATE346608T1 (de) 2006-12-15
FR10C0008I1 (fr) 2010-03-26
SI1162999T1 (sl) 2007-04-30
BRPI0009163B8 (pt) 2021-05-25
DE122009000054I1 (de) 2009-12-31
DK1163000T3 (da) 2008-04-28
WO2000056359A2 (en) 2000-09-28
BE1025464I2 (US07585860-20090908-C00162.png) 2019-03-06
AU750788B2 (en) 2002-07-25
EP1162999B1 (en) 2006-11-29
KR100642044B1 (ko) 2006-11-10
FR10C0008I2 (fr) 2012-10-26
TWI286938B (en) 2007-09-21
EP1163000A2 (en) 2001-12-19
WO2000056358A3 (en) 2001-01-04
CZ301445B6 (cs) 2010-03-03
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
JP5551579B2 (ja) 2014-07-16
CA2366314A1 (en) 2000-09-28
HK1043731A1 (en) 2002-09-27
AU3813600A (en) 2000-10-09
KR20020000549A (ko) 2002-01-05
PL355178A1 (en) 2004-04-05
LU91652I9 (US07585860-20090908-C00162.png) 2019-01-03
DE60038166T2 (de) 2009-03-12
LU91652I2 (fr) 2010-10-13
HU228499B1 (en) 2013-03-28
CY2009014I2 (el) 2010-07-28
HUP0200664A2 (en) 2002-06-29
JP2002540075A (ja) 2002-11-26
US20060002961A1 (en) 2006-01-05
HK1043730A1 (zh) 2002-09-27

Similar Documents

Publication Publication Date Title
BE2018C020I2 (US07585860-20090908-C00162.png)
BE2015C057I2 (US07585860-20090908-C00162.png)
BE2016C007I2 (US07585860-20090908-C00162.png)
BE2015C018I2 (US07585860-20090908-C00162.png)
BE2014C017I2 (US07585860-20090908-C00162.png)
BE2013C051I2 (US07585860-20090908-C00162.png)
BE2013C020I2 (US07585860-20090908-C00162.png)
BE2013C015I2 (US07585860-20090908-C00162.png)
BE2013C001I2 (US07585860-20090908-C00162.png)
BE2012C036I2 (US07585860-20090908-C00162.png)
BE2011C004I2 (US07585860-20090908-C00162.png)
BE2010C011I2 (US07585860-20090908-C00162.png)
BE2008C046I2 (US07585860-20090908-C00162.png)
BE1025464I2 (US07585860-20090908-C00162.png)
BRPI0017527B8 (US07585860-20090908-C00162.png)
BE2008C047I2 (US07585860-20090908-C00162.png)
BRPI0001672A2 (US07585860-20090908-C00162.png)
BRPI0001542A2 (US07585860-20090908-C00162.png)
JP2002521163A5 (US07585860-20090908-C00162.png)
BRPI0012675B8 (US07585860-20090908-C00162.png)
BRPI0017522A2 (US07585860-20090908-C00162.png)
HU0004772D0 (US07585860-20090908-C00162.png)
BRMU7902607U2 (US07585860-20090908-C00162.png)
CN3097870S (US07585860-20090908-C00162.png)
CN3098431S (US07585860-20090908-C00162.png)